TICKERNERD
Menu
CRBUCRBUHealthcare · Biotechnology

CRBU Stock Forecast: Caribou Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$1.58
−1.86% on the day

The 7 Wall Street analysts covering Caribou Biosciences, Inc. hold a median 12-month price target of $10 — +532.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$156.7M
Ticker Nerd rank
60 / 100
Median analyst target
$10
Analysts covering
7
Total return, dividends reinvested
1W
−4.2%
1M
−9.7%
YTD
−0.6%
1Y
−21.0%
From 52W high
−44.4%
From 52W low
+13.7%
$1.39
$2.84
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRBU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Caribou Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Revisions
83
Accruals
71
Size
70
Momentum
54
Volatility
29
Issuance
26
Value
22
Quality
19

Growth (99): Sales and profits are climbing, and climbing faster than before.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRBU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRBU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00Oct 25Jan 26Apr 26Jul 26CRBUHigh $32Median $10Low $4

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $4Median $10High $32

The green dot is the last close — the median target sits +532.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026B of A SecuritiesMaintainsBuy$6.00 → $5.00
11 May 2026HC Wainwright & Co.MaintainsBuy$9.00 → $11
7 Apr 2026HC Wainwright & Co.ReiteratesBuy—
9 Mar 2026Evercore ISI GroupMaintainsOutperform—
2 Feb 2026Clear StreetInitiatesBuy—
5 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Nov 2025CitigroupMaintainsBuy—
28 Apr 2025HC Wainwright & Co.MaintainsBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Jan 2025B of A SecuritiesMaintainsBuy—
26 Nov 2024CitigroupMaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
3 Sept 2024HC Wainwright & Co.ReiteratesBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
7 Aug 2024RBC CapitalReiteratesOutperform—
17 July 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.MaintainsBuy—
16 May 2024Truist SecuritiesMaintainsBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
19 Mar 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRBU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRBU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Caribou Biosciences, Inc. (CRBU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
16.9×

Cheaper than 10% of US stocks

Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−43.8%

Higher than 6% of US stocks

Earnings growth (YoY)
1.9%

Higher than 38% of US stocks

Gross margin
—
Operating margin
−1690.4%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−78.3%

Higher than 16% of US stocks

Return on assets
−36.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRBU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRBUCaribou Biosciences, Inc.$156.7M
60
CDXSCodexis, Inc.$167.8M
70
ARMPArmata Pharmaceuticals, Inc.$167.0M
66
NKTXNkarta, Inc.$166.1M
40
MDWDMediWound Ltd.$173.9M
29
HUMAHumacyte, Inc.$163.1M
18
OKUROnKure Therapeutics, Inc.$161.1M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Caribou Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRBU news & analysis

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026neutral

Caribou Biosciences reported a Q2 loss of $0.24 per share, narrower than the Zacks Consensus Estimate of a $0.33 loss and down from a $0.35 per-share loss a year earlier, though revenue lagged estimates.

Why it matters — The narrower-than-expected quarterly loss may signal improving operating performance, while the revenue shortfall highlights top-line headwinds investors in CRBU will want to monitor.

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Caribou Biosciences reported its Q2 2026 financial results and presented phase 1 data for vispa-cel at EHA 2026, which showed the therapy's safety, efficacy, and durability are comparable to approved autologous CAR-T cell therapies. The company also presented CaMMouflage dose escalation data for CB-011, with initial dose expansion data expected in the second half of 2026.

Why it matters — A CRBU watcher would care because the EHA 2026 data reinforce vispa-cel's potential to compete with approved CAR-T therapies and provide a timeline for CB-011's next data readout in high-risk multiple myeloma patients.

FAQ

Frequently asked questions about CRBU stock

What is the CRBU stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Caribou Biosciences, Inc. have a median 12-month price target of $10, with estimates ranging from $4 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRBU stock a buy right now?

Of the 7 analysts covering Caribou Biosciences, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caribou Biosciences, Inc. 60 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRBU?

As at 15 Aug 2026, Caribou Biosciences, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CRBU stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +532.9% from the last close, and Ticker Nerd's factor model ranks Caribou Biosciences, Inc. 60 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRBU stock forecast for 2030?

No analyst covering Caribou Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $32 over the next 12 months.

How has CRBU stock performed over the past year?

Caribou Biosciences, Inc. returned -21.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Caribou Biosciences, Inc. do?

Caribou Biosciences Inc. is at the forefront of biotechnology, specializing in genome-editing technologies.

What is the latest news on CRBU?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates". Caribou Biosciences reported a Q2 loss of $0.24 per share, narrower than the Zacks Consensus Estimate of a $0.33 loss and down from a $0.35 per-share loss a year earlier, though revenue lagged estimates.

Company

About Caribou Biosciences, Inc.

Caribou Biosciences Inc. is at the forefront of biotechnology, specializing in genome-editing technologies. This company primarily focuses on developing novel therapeutic solutions by leveraging CRISPR-derived gene-editing platforms. With its innovative approach, Caribou aims to address critical challenges in disease treatment, particularly in areas such as oncology and immunology. The company's pioneering work in advancing genetic therapies highlights its pivotal role in the rapidly evolving biotech sector. Caribou Biosciences collaborates with academic institutions and industry leaders to translate complex genomic research into tangible medical therapies, fostering advancements in personalized medicine. The company's deep commitment to scientific excellence propels its influence in the gene-editing landscape, highlighting its importance in the nascent yet potent therapeutic area of genome manipulation. By steering the development of cutting-edge gene-editing applications, Caribou Biosciences is instrumental in shaping the future of bioengineering and therapeutic interventions.

CEO Dr. Rachel E. Haurwitz Ph.D. · 97 employees · United States · https://cariboubio.com